Are proton pump inhibitors really so dangerous?

Digestive and Liver Disease

Volumn 48, Issue 8, 2016, Pages 851-859

  Savarino, Vincenzo ^a   Dulbecco, Pietro ^a   Savarino, Edoardo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adverse events; Gastro oesophageal reflux disease; GERD; H2 receptor antagonists; PPI

Indexed keywords

CALCIUM; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

CHRONIC KIDNEY DISEASE; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; HIP FRACTURE; HUMAN; HYPOMAGNESEMIA; INTESTINE INFECTION; ISCHEMIC HEART DISEASE; NUTRITIONAL DEFICIENCY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STOMACH ACID SECRETION; STOMACH CARCINOID; BACTERIAL INFECTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROESOPHAGEAL REFLUX; HIP FRACTURES; MALNUTRITION; MYOCARDIAL ISCHEMIA; RENAL INSUFFICIENCY, CHRONIC; VITAMIN B 12 DEFICIENCY;

BACTERIAL INFECTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROESOPHAGEAL REFLUX; HIP FRACTURES; HISTAMINE H2 ANTAGONISTS; HUMANS; MALNUTRITION; MYOCARDIAL ISCHEMIA; PNEUMONIA; PROTON PUMP INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN B 12 DEFICIENCY;

EID: 84990945103     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.05.018     Document Type: Review

References (78)

1. [1] Schubert, M.L., Peura, D.A., Control of gastric acid secretion in health and disease. Gastroenterology 134 (2008), 1842–1860.
2. [2] Malfertheiner, P., Megraud, F., O'Morain, C.A., et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 61 (2012), 646–664.
3. [3] Yang, Y.X., Metz, D.C., Safety of proton pump inhibitor exposure. Gastroenterology, 139, 2010, 27.
4. [4] Imhann, F., Bonder, M.J., Vich Vila, A., et al. Proton pump inhibitors affect the gut microbiome. Gut, 2015, 10.1136/gutjnl-2015-310376.
5. [5] Lombardo, L., Foti, M., Ruggia, O., et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clinical Gastroenterology and Hepatology 8 (2010), 504–508.
6. [6] Compare, D., Pica, L., Rocco, A., et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation 41 (2011), 380–386.
7. [7] Parodi, A., Sessarego, M., Greco, A., et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. American Journal of Gastroenterology 103 (2008), 1257–1262.
8. [8] Nwokolo, C., Loft, D., Holder, R., et al. Increased incidence of bacterial diarrhea in patients taking gastric acid antisecretory drugs. European Journal of Gastroenterology and Hepatology 6 (1994), 697–699.
9. [9] Garcia Rodriguez, L.A., Ruigomez, A., Panes, J., Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clinical Gastroenterology and Hepatology 5 (2007), 1418–1423.
10. [10] Sheen, E., Triadafilopoulos, G., Adverse effects of long-term proton pump inhibitor therapy. Digestive Diseases and Sciences 56 (2011), 931–950.
11. [11] Deshpande, A., Pant, C., Pasupuleti, V., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clinical Gastroenterology and Hepatology 10 (2012), 225–233.
12. [12] Leonard, J., Marshall, J.K., Moayyedi, P., Systematic review of the risk on enteric infection in patients taking acid suppression. American Journal of Gastroenterology 102 (2007), 2047–2056.
13. [13] Dial, M.S., Proton pump inhibitor use and enteric infections. American Journal of Gastroenterology 104 (2009), S10–S16.
14. [14] Choudhry, M.N., Soran, H., Ziglam, H.M., Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. Quarterly Journal of Medicine 101 (2008), 445–448.
15. [15] Trikudanathan, G., Israel, J., Cappa, J., et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta-analysis. International Journal of Clinical Practice 65 (2011), 674–678.
16. [16] Siple, J.F., Morey, J.M., Gutman, T.E., et al. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Annals of Pharmacotherapy 46 (2012), 1413–1418.
17. [17] Xu, H.B., Wang, H.D., Li, C.H., et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genetics and Molecular Research 14 (2015), 7490–7501.
18. [18] Sharara, A.I., Chalhoub, J.M., Hammoud, N., et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clinical Gastroenterology and Hepatology 14 (2016), 317–321.
19. [19] Quamme, G.A., Recent developments in intestinal magnesium absorption. Current Opinion in Gastroenterology 24 (2008), 230–235.
20. [20] Hess, M.W., Hoenderop, J.G.J., Bindels, R.J.M., et al. Systematic review: hypomagnesemia induced by proton pump inhibition. Alimentary Pharmacology and Therapeutics 36 (2012), 405–413.
21. [21] Yang, Y.X., Lewis, J.D., Epstein, S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 (2006), 2947–2953.
22. [22] Vestergaard, P., Rejnmark, L., Mosekilde, L., Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcified Tissue International, 79, 2006, 83.
23. [23] Targownik, L.E., Lix, L.M., Metge, C.J., et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Canadian Medical Association Journal 179 (2008), 319–326.
24. [24] Targownik, L.E., Lix, L.M., Leung, S., et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138 (2010), 896–904.
25. [25] Ye, X., Liu, H., Wu, C., et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology 23 (2011), 794–800.
26. [26] Ngamruengphong, S., Leontiadis, G.I., Radhi, S., et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. American Journal of Gastroenterology 106 (2011), 1209–1218.
27. [27] Corley, D.A., Kubo, A.I., Zhao, W., et al. Proton pump inhibitors and histamine H2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139 (2010), 93–101.
28. [28] Kaye, J.A., Jick, H., Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28 (2008), 951–959.
29. [29] O'Connell, M.B., Madden, D.M., Murray, A.M., et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. American Journal of Medicine 118 (2005), 778–781.
30. [30] Tuukkanen, J., Vaananen, H.K., Omeprazole, a specific inhibitor of H+ K+ ATPase, inhibits bone resorption in vitro. Calcified Tissue International 38 (1986), 123–125.
31. [31] Yu, E.W., Blackwell, T., Ensrud, K.E., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcified Tissue International 83 (2008), 251–259.
32. [32] Filion, K.B., Chateau, D., Targownik, L.E., et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 63 (2014), 552–558.
33. [33] Gulmez, S.E., Holm, A., Frederiksen, H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Archives of Internal Medicine 167 (2007), 950–955.
34. [34] Laheij, R.I., Sturkenboom, M.C., Hassing, R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004), 1955–1960.
35. [35] Sarkar, M., Hennessy, S., Yang, Y.X., Proton-pump inhibitor use and the risk for community-acquired pneumonia. Annals of Internal Medicine 149 (2008), 391–398.
36. [36] Johnstone, J., Nerenberg, K., Loeb, M., Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Alimentary Pharmacology and Therapeutics 31 (2010), 1165–1177.
37. [37] De Jager, C.P.C., Wever, P.C., Gemen, E.F.A., et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Alimentary Pharmacology and Therapeutics 36 (2012), 941–949.
38. [38] Lundell, L., Miettine, P., Myrvold, H.E., et al. Seven-year follow-up of a randomized clinical trial comparing proton pump inhibition with surgical therapy for reflux esophagitis. British Journal of Surgery 94 (2007), 198–203.
39. [39] Lundell, L., Attwood, S., Ell, C., et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 57 (2008), 1207–1213.
40. [40] Savarino, V., Di Mario, F., Scarpignato, C., Proton pump inhibitor in GORD: an overview of their pharmacology, efficacy and safety. Pharmacological Research 59 (2009), 135–153.
41. [41] Ho, P.M., Maddox, T.M., Wang, L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009), 937–944.
42. [42] Alkhatib, A.A., Elkhatib, F.A., Khatib, O.F., Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?. American Journal of Gastroenterology, 105, 2010, 1211.
43. [43] Charlot, M., Alhehoff, O., Norgaard, M.L., et al. Proton pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Annals of Internal Medicine 153 (2010), 378–386.
44. [44] Shah, N.H., LePendu, P., Bauer-Mehren, A., et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLOS ONE, 10, 2015, e124653.
45. [45] Ghebrenariam, Y.T., Le Pendu, P., Lee, J.C., et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128 (2013), 845–853.
46. [46] Syed, A.R., Wolfe, M.R., Wolfe, M.M., A retrospective analysis of the effect of long-term proton pump inhibitor (PPI) use on the prevalence of ischemic heart disease (IHD). Gastroenterology, 150(Suppl. 1), 2016, S216.
47. [47] Myers, R.P., McLaughlin, K., Hollomby, D.J., Acute interstitial nephritis due to omeprazole. American Journal of Gastroenterology 96 (2001), 3428–3431.
48. [48] Geevasinga, N., Coleman, P.L., Webster, A.C., et al. Proton pump inhibitors and acute interstitial nephritis. Clinical Gastroenterology and Hepatology 4 (2006), 597–604.
49. [49] Lazarus, B., Chen, Y., Wilson, F., et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 2016, 10.1001//jamainternmed2015.7193.
50. [50] Saltzman, J.R., Kemp, J.A., Golner, B.B., et al. Effect of hypochlorydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. Journal of the American College of Nutrition 13 (1994), 584–591.
51. [51] Schenk, B.E., festen, H.P., Kuipers, E.J., et al. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Alimentary Pharmacology and Therapeutics 10 (1996), 541–545.
52. [52] Kittang, E., Aadland, E., Schjonsby, H., et al. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scandinavian Journal of Gastroenterology 22 (1987), 156–160.
53. [53] Den Elzen, W.P., Groeneveld, Y., de Rujiter, W., et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Alimentary Pharmacology and Therapeutics 27 (2008), 491–497.
54. [54] Valuck, R.J., Ruscin, J.M., A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. Journal of Clinical Epidemiology 57 (2004), 422–428.
55. [55] Hirshowitz, B.I., Worthington, J., Mohnen, J., Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology and Therapeutics 27 (2008), 1110–1121.
56. [56] Sheikh, M.S., Santa Ana, C.A., Nicar, M.J., et al. Gastrointestinal absorption of calcium from milk and calcium salts. New England Journal of Medicine 317 (1987), 532–536.
57. [57] Champagne, E.T., Low gastric hydrochloric acid secretion and mineral bioavailability. Advances in Experimental Medicine and Biology 249 (1989), 173–184.
58. [58] Reimer, C., Safety of long-term PPI therapy. Best Practice and Research: Clinical Gastroenterology 27 (2013), 443–454.
59. [59] Gomm, W., von Holt, K., Thomè, F., et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology, 2016, 10.1001/jamaneurol.2015.4791.
60. [60] Haenisch, B., von Holt, K., Wiese, B., et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience 265 (2015), 419–428.
61. [61] Badiola, N., Alcade, V., Pujol, A., et al. The proton pump inhibitor lansoprazole enhances amyloid beta production. PLOS ONE, 8, 2013, e58837.
62. [62] Boustain, M., Halls, K.S., Lane, K.A., et al. The association between cognition and histamine 2 – receptor antagonists in African Americans. Journal of the American Geriatrics Society 55 (2007), 248–253.
63. [63] Agray, S.L., Walker, R., Dublin, S., et al. Histamine 2 – receptor antagonist use and incident dementia in an older cohort. Journal of the American Geriatrics Society 59 (2011), 251–257.
64. [64] Pounder, R., Smith, J., Drug-induced changes of plasma gastrin concentration. Gastroenterology Clinics of North America 19 (1990), 141–153.
65. [65] Laine, L., Ahnen, D., McClain, C., et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology and Therapeutics 14 (2000), 651–668.
66. [66] Havu, N., Mattson, H., Ekman, L., et al. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45 (1990), 189–195.
67. [67] Simonsson, M., Eriksson, S., Hakanson, R., et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scandinavian Journal of Gastroenterology 23 (1988), 1089–1099.
68. [68] Freston, J.W., Clinical significance of hypergastrinemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 51:Suppl. 1 (1992), 102–114.
69. [69] Kuipers, E.J., Uyterlinde, A.M., Pena, A.S., et al. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: implications for long-term safety. American Journal of Gastroenterology 90 (1995), 1402–1406.
70. [70] Rao, S.S., Nayak, K.S., Swarnalata, G., et al. Gastric carcinoid associated with ranitidine in a patient with renal failure. American Journal of Gastroenterology 88 (1993), 1273–1274.
71. [71] Dawson, R., Manson, J.M., Omeprazole in oesophageal reflux disease. Lancet 356 (2000), 1770–1771.
72. [72] Haga, Y., Nakatsura, T., Shibata, Y., et al. Human gastric carcinoid detected during long-term anti-ulcer therapy of H2-receptor antagonist and proton pump inhibitor. Digestive Diseases and Sciences 43 (1998), 253–257.
73. [73] Jianu, C.S., Lange, O.J., Viset, T., et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scandinavian Journal of Gastroenterology 47 (2012), 64–67.
74. [74] Jianu, C.S., Fossmark, R., Viset, T., et al. Gastric carcinoids after long-term use of proton pump inhibitor. Alimentary Pharmacology and Therapeutics 36 (2012), 644–649.
75. [75] Lahner, E., Pilozzi, E., Esposito, G., et al. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. Scandinavian Journal of Gastroenterology 49 (2014), 506–510.
76. [76] Cavalcoli, F., Zilli, A., Conte, D., et al. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence. Scandinavian Journal of Gastroenterology 50 (2015), 1397–1403.
77. [77] Nandy, N., Hanson, J.A., Strickland, R.G., et al. Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Digestive Diseases and Sciences 61 (2016), 708–712.
78. [78] Yeomans, N.D., Dent, J., Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion. Alimentary Pharmacology and Therapeutics 14 (2000), 267–271.